NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
NeOnc Technologies Holdings (NTHI) has appointed Dr. Steven L. Giannotta, former Chair of Neurological Surgery at USC, to its Board of Directors. Dr. Giannotta brings over 40 years of expertise in cerebrovascular and cranial base surgery to the clinical-stage medical biotechnology company.
Dr. Giannotta is internationally recognized for pioneering 'hyperdynamic therapy' for cerebral vasospasm and has performed over 1,000 intracranial aneurysm surgeries. His research focuses on cerebral blood flow, ischemia, and ethnic differences in cerebrovascular disorders.
The appointment aligns with NeOnc's mission of pursuing innovative solutions in neurosurgical care. Dr. Giannotta joined USC's Department of Neurosurgery in 1980 and has developed a comprehensive, multidisciplinary approach to complex cerebrovascular conditions.
NeOnc Technologies Holdings (NTHI) ha nominato il Dr. Steven L. Giannotta, ex Presidente della Chirurgia Neurologica presso l'USC, nel suo Consiglio di Amministrazione. Il Dr. Giannotta porta oltre 40 anni di esperienza nella chirurgia cerebrovascolare e della base cranica alla società di biotecnologia medica in fase clinica.
Il Dr. Giannotta è riconosciuto a livello internazionale per aver pionierato la 'terapia iperdinamica' per il vasospasmo cerebrale e ha eseguito oltre 1.000 interventi chirurgici su aneurismi intracranici. La sua ricerca si concentra sul flusso sanguigno cerebrale, l'ischemia e le differenze etniche nei disturbi cerebrovascolari.
La nomina è in linea con la missione di NeOnc di perseguire soluzioni innovative nella cura neurochirurgica. Il Dr. Giannotta è entrato a far parte del Dipartimento di Neurochirurgia dell'USC nel 1980 e ha sviluppato un approccio multidisciplinare completo per le condizioni cerebrovascolari complesse.
NeOnc Technologies Holdings (NTHI) ha nombrado al Dr. Steven L. Giannotta, ex Presidente de Cirugía Neurológica en USC, a su Junta Directiva. El Dr. Giannotta aporta más de 40 años de experiencia en cirugía cerebrovascular y de base craneal a la empresa de biotecnología médica en etapa clínica.
El Dr. Giannotta es reconocido internacionalmente por ser pionero en la 'terapia hiperdinámica' para el vasoespasmo cerebral y ha realizado más de 1,000 cirugías de aneurisma intracraneal. Su investigación se centra en el flujo sanguíneo cerebral, la isquemia y las diferencias étnicas en los trastornos cerebrovasculares.
El nombramiento se alinea con la misión de NeOnc de buscar soluciones innovadoras en el cuidado neuroquirúrgico. El Dr. Giannotta se unió al Departamento de Neurocirugía de USC en 1980 y ha desarrollado un enfoque multidisciplinario integral para las condiciones cerebrovasculares complejas.
NeOnc Technologies Holdings (NTHI)는 USC의 신경외과 전 의장인 스티븐 L. 지아노타 박사를 이사회에 임명했습니다. 지아노타 박사는 40년 이상의 경험을 가진 뇌혈관 및 두개 기저 수술 전문가로서 임상 단계의 의료 생명공학 회사에 합류했습니다.
지아노타 박사는 뇌혈관 경련에 대한 '하이퍼다이나믹 요법'을 개척한 것으로 국제적으로 인정받고 있으며, 1,000건 이상의 두개내 동맥류 수술을 수행했습니다. 그의 연구는 뇌혈류, 허혈 및 뇌혈관 질환에 대한 민족적 차이에 중점을 두고 있습니다.
이번 임명은 신경외과 치료에서 혁신적인 솔루션을 추구하는 NeOnc의 사명과 일치합니다. 지아노타 박사는 1980년 USC 신경외과에 합류하여 복잡한 뇌혈관 질환에 대한 포괄적이고 다학제적인 접근 방식을 개발했습니다.
NeOnc Technologies Holdings (NTHI) a nommé le Dr Steven L. Giannotta, ancien président de la chirurgie neurologique à l'USC, au sein de son conseil d'administration. Le Dr Giannotta apporte plus de 40 ans d'expertise en chirurgie cerebrovasculaire et de base crânienne à cette entreprise de biotechnologie médicale en phase clinique.
Le Dr Giannotta est reconnu internationalement pour avoir été le pionnier de la 'thérapie hyperdynamique' pour le vasospasme cérébral et a réalisé plus de 1 000 interventions chirurgicales sur des anévrismes intracrâniens. Ses recherches portent sur le flux sanguin cérébral, l'ischémie et les différences ethniques dans les troubles cerebrovasculaires.
Cette nomination s'inscrit dans la mission de NeOnc de rechercher des solutions innovantes en matière de soins neurochirurgicaux. Le Dr Giannotta a rejoint le département de neurochirurgie de l'USC en 1980 et a développé une approche multidisciplinaire complète pour les conditions cerebrovasculaires complexes.
NeOnc Technologies Holdings (NTHI) hat Dr. Steven L. Giannotta, ehemaligen Vorsitzenden der Neurochirurgie an der USC, in seinen Vorstand berufen. Dr. Giannotta bringt über 40 Jahre Erfahrung in der cerebrovaskulären und kranialen Basischirurgie in das klinische Biotechnologieunternehmen ein.
Dr. Giannotta ist international anerkannt für die Pionierarbeit in der 'hyperdynamischen Therapie' bei zerebralen Vasospasmen und hat über 1.000 intrakranielle Aneurysmen-Operationen durchgeführt. Seine Forschung konzentriert sich auf den zerebralen Blutfluss, Ischämie und ethnische Unterschiede bei cerebrovaskulären Erkrankungen.
Die Ernennung steht im Einklang mit NeOncs Mission, innovative Lösungen in der neurochirurgischen Versorgung zu verfolgen. Dr. Giannotta trat 1980 in die Abteilung für Neurochirurgie der USC ein und entwickelte einen umfassenden, multidisziplinären Ansatz für komplexe cerebrovaskuläre Erkrankungen.
- Addition of highly experienced neurosurgeon with over 40 years expertise to Board of Directors
- Strengthened leadership team with expertise directly relevant to company's focus area
- Access to extensive clinical experience (1,000+ intracranial aneurysm surgeries)
- Upcoming NASDAQ listing indicates potential for increased visibility and access to capital
- Company still in clinical-stage with no marketed products
- Pending NASDAQ listing suggests current absence from major exchanges
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced the appointment of Dr. Steven L. Giannotta, a distinguished neurosurgeon and former Chair of Neurological Surgery at the University of Southern California (USC), to its Board of Directors. Dr. Giannotta brings over four decades of expertise in cerebrovascular and cranial base surgery, with contributions to cerebral blood flow research, ischemia prevention, and innovative surgical techniques.
“Steven’s extensive background in neurological surgery, especially his leadership in advancing both research and surgical techniques for cerebrovascular diseases, will be invaluable to our Company,” said Dr. Thomas Chen, CEO of NeOnc. “We look forward to having his expertise and visionary perspective shape our progress as we continue to advance our mission of pursuing innovative solutions that enhance patient care, bring hope, and extend lives."
Dr. Giannotta joined the USC Department of Neurosurgery in 1980, and has since become internationally recognized for his groundbreaking work in cerebrovascular disease, including pioneering "hyperdynamic therapy" as a clinical approach to combat cerebral vasospasm. His research interests encompass cerebral blood flow, ischemia, and the impact of ethnic differences on cerebrovascular disorders. Dr. Giannotta's clinical achievements include performing over 1,000 intracranial aneurysm surgeries and developing a comprehensive, multidisciplinary approach to complex cerebrovascular conditions.
"I am thrilled to be a part of NeOnc's Board of Directors,” said Dr. Giannotta. "I have spent my entire professional career on development of dynamic therapies, and believe NeOnc is on the right path with the same mission.”
"Dr. Giannotta’s dedication to improving patient outcomes and pioneering innovative approaches aligns seamlessly with our core values,” said Amir Heshmatpour, Executive Chairman of NeOnc. “We believe his wealth of experience in managing complex cerebrovascular conditions will greatly enhance our ability to deliver cutting-edge solutions in neurosurgical care."
Dr. Giannotta earned his medical degree, and completed his residency, at the University of Michigan. He remains deeply engaged with several national and international neurosurgical committees, furthering both clinical advancements and educational initiatives in his field.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com
lberman@pondel.com
FAQ
What expertise does Dr. Giannotta bring to NTHI's Board of Directors?
What is Dr. Giannotta's breakthrough contribution to cerebrovascular disease treatment?
When will NTHI be listed on the NASDAQ Global Market?
What are Dr. Giannotta's main research interests at NTHI?
